A drug discovery and development company with “first-in-class” drugs for respiratory diseases
Investors
Verona Pharma is listed on the London Stock Exchange under the VRP.L ticker. Read more here about investing in Verona Pharma
Verona Pharma shares
Downloads
View Webcast of 2013 Full Year Results Presentation to Analysts
2013 Full Year Results Presentation to Analysts (28 April 2014)
Partners
A key component of Verona Pharma’s business strategy is out-licensing its “first-in-class” drug programmes to suitable development and commercialisation partners. To discuss partnering opportunities, please contact This email address is being protected from spambots. You need JavaScript enabled to view it.
Events and Media
Follow the links below for more information about specific events:
- Dr. Jan-Anders Karlsson presents at the Asthma and COPD Conference
- Dr. Jan-Anders Karlsson presents at Therapeutic Area Partnerships
- Listen to Professor Page discussing the findings on RPL554 with The Lancet Respiratory Medicine
- ATS Conference
- Professor Clive Page gives Plenary Lecture on PDE inhibitors at ASPET 21 April 2013
- Interview with Dr. Jan-Anders Karlsson, published in the January/February 2013 issue of sp2 Inter-Active
- ERS Conference
- ISAF Conference
Verona Pharma plc, Suite 21 - Alpha House, 100 Borough High Street. London SE1 1LB
Email:
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Tel: +44 (0)20 7863 3300 | Fax: +44 (0)20 7863 3314
To provide feedback or report problems with the website:
This email address is being protected from spambots. You need JavaScript enabled to view it.